Clinical Exercise Testing 2002
DOI: 10.1159/000062213
|View full text |Cite
|
Sign up to set email alerts
|

Evolving Role of Cardiopulmonary Exercise Testing in Heart Failure and Cardiac Transplantation

Abstract: Heart failure (HF) is a multiorgan syndrome and the cardiopulmonary exercise test (CPET) provides an overall assessment of functional capacity and prognosis. From a prognostic point of view, useful information is obtained from peak VO 2 and VE/VCO 2 slope. These are independent predictors of survival in patients with HF and can be combined with other prognostic elements. Furthermore, CPET allows to identify the organ which is most responsible for HF severity and to target therapy on. Indeed, the following are … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
1
0
1

Year Published

2009
2009
2020
2020

Publication Types

Select...
4
1

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(2 citation statements)
references
References 75 publications
0
1
0
1
Order By: Relevance
“…The rate of rise of exceeds the rate of rise of and so / starts to increase. This gives one method of determining the VAT from gas exchange measurements as AT is the point when the Ventilatory Equivalent for oxygen (/) increases relative to a constant Ventilatory Equivalent for carbon dioxide (/) [14] (Fig. 3).…”
Section: Physiology Of the Anaerobic Thresholdmentioning
confidence: 99%
“…The rate of rise of exceeds the rate of rise of and so / starts to increase. This gives one method of determining the VAT from gas exchange measurements as AT is the point when the Ventilatory Equivalent for oxygen (/) increases relative to a constant Ventilatory Equivalent for carbon dioxide (/) [14] (Fig. 3).…”
Section: Physiology Of the Anaerobic Thresholdmentioning
confidence: 99%
“…Somit kann die Effi zienz auch zur Objektivierung des Gehtests in dieser Patientengruppe angewendet werden. Best ä tigt werden diese Ergebnisse durch Untersuchungen von Agostoni und Guazzi [37] und einer doppelblinden Plazebo-kontrollierten Carvedilol-Studie [38] , die keinen wesentlichen Einfl uss der Betablocker-Therapie auf die Ergebnisse der ergospirometrisch erfassten Leistungsf ä higkeit zeigten. Auch Kroidl et al [39] stellen in ihrem Kursbuch Ergospirometrie fest, dass Betablocker keine relevanten Einschr ä nkungen in der Ergospirometrie bewirken.…”
Section: Auswirkungen Einer Betablocker-therapieunclassified